Skip to main content

Articles

Page 5 of 11

  1. Despite the fact that the fundamental characteristics of coronavirus disease-2019 (COVID-19) are respiratory manifestations, multi-organ failure including the kidney has been documented. There are no clear com...

    Authors: Enass E. El-Sayed, Abdou K. Allayeh, Amany A. Salem, Sheren M. Omar, Salwa M. Zaghlol, Hala M. Abd-Elmaguid, Mohammed M. Abdul-Ghaffar and Magdy M. ElSharkawy
    Citation: Renal Replacement Therapy 2021 7:32
  2. Malnutrition that is associated with inflammation is a key factor of poor outcome in chronic hemodialysis patients, especially in older dialysis patients. Polymethyl methacrylate (PMMA) membrane has been repor...

    Authors: Ikuto Masakane, Ichiro Yamaguchi, Yuji Matsumoto, Ken Ataka, Yuta Oyama, Michio Nagaoka, Yasushi Matsushita, Tomoko Teramura, Koji Seino, Hiroyuki Amano and Ai Kobayashi
    Citation: Renal Replacement Therapy 2021 7:31
  3. Patients with chronic kidney disease often suffer from cardiovascular disease, and vascular calcification has been identified as one of the risk factors for cardiovascular disease. We aimed to examine the effe...

    Authors: Kentaro Nakai, Shutaro Yamamoto, Megumi Inoue, Chiaki Kohara, Tomoya Shukuri, Kentaro Motoyama and Koji Mitsuiki
    Citation: Renal Replacement Therapy 2021 7:30
  4. In order to facilitate the safe and long-term delivery of peritoneal dialysis (PD), it is necessary to improve the biocompatibility of peritoneal dialysis fluids (PDFs). The novel bicarbonate/lactate-buffered ...

    Authors: Hiromichi Ueno, Tetsu Miyamoto, Hiroyuki Morimoto, Kenya Sanada, Ikutaro Furuno, Kazutoshi Nakazono, Emi Hasegawa, Akihiro Kuma, Yasushi Oginosawa, Yuki Tsuda, Masaru Araki, Masahito Tamura, Yoichi Ueta, Yutaka Otsuji and Masaharu Kataoka
    Citation: Renal Replacement Therapy 2021 7:29
  5. The prevalence of end-stage kidney disease (ESKD) is growing worldwide; the survival of these patients requires renal replacement therapy (RRT, a complex and costly treatment). Over 20% of the patients that st...

    Authors: Isabella Vanorio-Vega, Panayotis Constantinou, Philippe Tuppin and Cécile Couchoud
    Citation: Renal Replacement Therapy 2021 7:28
  6. Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic affecting a variety of medical treatments, including hemodialysis. This...

    Authors: Yuka Sugawara, Masao Iwagami, Kan Kikuchi, Yoko Yoshida, Ryoichi Ando, Toshio Shinoda, Munekazu Ryuzaki, Hidetomo Nakamoto, Ken Sakai, Norio Hanafusa, Naoki Kashihara and Masaomi Nangaku
    Citation: Renal Replacement Therapy 2021 7:27
  7. Low-ionized magnesium and high-ionized calcium levels are associated with increased cardiovascular mortality in patients undergoing dialysis. We examined the effects of the dilution method, substitution volume...

    Authors: Yusaku Tanaka, Hisato Shima, Ryosuke Hatonari, Daisuke Okada, Hiroyuki Michiwaki, Seiichiro Wariishi, Tomohiro Tao and Jun Minakuchi
    Citation: Renal Replacement Therapy 2021 7:26
  8. Peritoneal dialysis (PD)-related peritonitis risk factors can be categorized as modifiable and uncorrectable. We aimed to identify modifiable risk factors for PD-related peritonitis in our facility to prevent ...

    Authors: Shigeki Kojima, Shohei Yamada, Rie Fujishima, Kenichiro Koitabashi, Yugo Shibagaki and Tsutomu Sakurada
    Citation: Renal Replacement Therapy 2021 7:25
  9. Hemodialysis-associated pruritus (HAP) is a serious complication that occurs in 60–80% of hemodialysis patients, which not only decreases quality of life but also worsens prognosis. We have developed a treatme...

    Authors: Naoko Takahashi, Taku Yoshizawa, Junko Kumagai, Hideki Kawanishi, Shinichiro Tsuchiya, Misaki Moriishi and Takao Masaki
    Citation: Renal Replacement Therapy 2021 7:24
  10. According to the annual survey of the Japanese Society for Dialysis Therapy Renal Data Registry (JRDR) conducted at the end of 2018, a total of 339,841 patients were receiving dialysis (hereinafter, dialysis p...

    Authors: Kosaku Nitta, Shigeru Nakai, Ikuto Masakane, Norio Hanafusa, Shunsuke Goto, Masatomo Taniguchi, Takeshi Hasegawa, Atsushi Wada, Takayuki Hamano, Junichi Hoshino, Nobuhiko Joki, Keichi Yamamoto, Kenichiro Miura, Masanori Abe and Hidetomo Nakamoto
    Citation: Renal Replacement Therapy 2021 7:22
  11. Intradialytic exercises are recommended to be available as a treatment for enhancing physical functioning. However, there have been few reports which evaluated the results of long-term mild intradialytic exerc...

    Authors: Masahiro Kato, Masanori Shibata, Kazuaki Asai, Kumi Harada, Isao Ito, Hisae Tawada, Kojiro Nagai and Shinkichi Taniguchi
    Citation: Renal Replacement Therapy 2021 7:21
  12. In the development of medical devices usability is an important aspect standing alongside performance and safety. Peritoneal dialysis (PD) can be provided by use of automated PD (APD), assisted by a cycler per...

    Authors: Thore Reitz, Stephanie Schwenke, Sebastian Hölzle and Adelheid Gauly
    Citation: Renal Replacement Therapy 2021 7:20
  13. During the outbreak of new coronavirus pneumonia, many hospitals in China became the designated hospitals for the treatment of new coronavirus pneumonia. The goal was to develop rapid and effective prevention ...

    Authors: Jinmei Yin, Jun Yin, Zhiwu Tian, Peiqiu Li and Xiaoqiu Chen
    Citation: Renal Replacement Therapy 2021 7:19
  14. Intradialytic hypotension (IDH) is one of the most frequent complications of hemodialysis. IDH alters a patient’s quality of life and has a strong association with mortality. IDH mainly occurs when ultrafiltra...

    Authors: Yumi Aoyama, Katsuya Kajimoto, Maiko Hori, Shigeru Otsubo and Kosaku Nitta
    Citation: Renal Replacement Therapy 2021 7:18
  15. Adrenal insufficiency causes abnormal subjective symptoms such as general fatigue, signs such as hypotension, and abnormalities such as hypoglycemia and leads to poor prognosis. However, all these are also obs...

    Authors: Naro Ohashi, Yukitoshi Sakao, Taichi Sato, Sayaka Ishigaki, Shinsuke Isobe, Tomoyuki Fujikura, Akihiko Kato and Hideo Yasuda
    Citation: Renal Replacement Therapy 2021 7:17
  16. Some types of antihypertensive drugs may have pleiotropic effects in patients with chronic kidney disease (CKD). However, whether triple combination therapy with angiotensin II receptor blockers (ARBs), calciu...

    Authors: Sakuya Ito, Yosuke Nakayama, Goh Kodama, Kanji Ota, Kensei Taguchi, Yusuke Kaida, Sho-ichi Yamagishi and Kei Fukami
    Citation: Renal Replacement Therapy 2021 7:16
  17. Multiple organ dysfunction syndrome is the leading cause of death in pediatric intensive care units and can be very critical when combined with shock and disseminated intravascular coagulation (DIC). Currently...

    Authors: Hiroyuki Nagafuchi, Hiroyuki Shimizu, Kaori Yamada, Kenta Shono and Tetsuya Ogawa
    Citation: Renal Replacement Therapy 2021 7:15
  18. More than three hundred thousand hemodialysis (HD) patients exist in Japan. The average of vintage of Japanese hemodialysis patients was longer than Western country. Longer and older hemodialysis patients tend...

    Authors: Takeshi Nakata, Hirotaka Shibata, Yuji Kamijo and Tsuneo Konta
    Citation: Renal Replacement Therapy 2021 7:14
  19. Responsiveness to erythropoiesis-stimulating agents (ESAs) is thought to be related to prognosis in patients on hemodialysis. A multi-center, prospective cohort study was conducted to investigate the effects o...

    Authors: Kenichi Tanaka, Momoko Fujiwara, Hirotaka Saito, Tsuyoshi Iwasaki, Akira Oda, Shuhei Watanabe, Makoto Kanno, Hiroshi Kimura, Yoshihiro Tani, Jun Asai, Hodaka Suzuki, Keiji Sato and Junichiro James Kazama
    Citation: Renal Replacement Therapy 2021 7:13
  20. The impact of end-stage renal disease on the patient’s psychological status necessitates the value of increasing depression awareness. The current study aimed to assess the depression prevalence among Palestin...

    Authors: Samah W. Al-Jabi, Ansam Sous, Fatimah Jorf, Mahmoud Taqatqa, Mahdi Allan, Lamees Sawalha, Enas Lubadeh, Waleed M. Sweileh and Sa’ed H. Zyoud
    Citation: Renal Replacement Therapy 2021 7:12
  21. Online hemodiafiltration (OL-HDF), whether in pre-dilution OL-HDF (pre-HDF) or post-dilution OL-HDF (post-HDF), is conducted to efficiently remove low molecular weight proteins from the blood of patients requi...

    Authors: Kenji Sakurai, Hiromi Hosoya, Yoshitaka Kurihara and Takeshi Saito
    Citation: Renal Replacement Therapy 2021 7:10
  22. To manage the anemic status in hemodialysis (HD) patients, a well-balanced combination therapy based on the use of erythropoiesis-stimulating agents (ESAs) and iron supplementation is essential. Serum ferritin...

    Authors: Kumiko Onda, Teruo Koyama, Sanae Kobayashi, Yoji Ishii and Kazuo Ohashi
    Citation: Renal Replacement Therapy 2021 7:9
  23. In continuous renal replacement therapy (CRRT), administration of anticoagulants is necessary for achieving a certain level of filter lifetime. Generally, anticoagulant doses are controlled to keep activated p...

    Authors: Hiroko Yuzawa, Yousuke Hirose, Tomonori Kimura, Keisuke Shinozaki, Moe Oguchi, Tomohiro Morito and Tomohito Sadahiro
    Citation: Renal Replacement Therapy 2021 7:7
  24. Dialysis patients have to take many oral drugs, causing a high pill burden. Phosphate binders (PBs) account for a large proportion of daily pill burden; however, the relationship between patient background and...

    Authors: Nobuo Nagano, Kyoko Ito, Takashi Ono, Yuichi Ariyoshi, Soichiro Masima, Hajime Kobayashi, Tetsuo Ando, Takaaki Tsutsui and Tetsuya Ogawa
    Citation: Renal Replacement Therapy 2021 7:5
  25. Quality of life for haemodialysis (HD) patients may be affected by symptoms during dialysis treatments, and patient groups have highlighted the need to improve post-dialysis fatigue and dialysis-related sympto...

    Authors: Suree Yoowannakul, Surachet Vongsanim, Kamonwan Tangvoraphonkchai, Ahmed Mohamed and Andrew Davenport
    Citation: Renal Replacement Therapy 2021 7:4
  26. Renal anemia is the important complication in patients undergoing peritoneal dialysis (PD), and heart failure (HF) is the important complication in patients on dialysis. Decreasing endogenous erythropoietin (E...

    Authors: Kohsuke Terada, Yuichiro Sumi, Sae Aratani, Akio Hirama, Tetsuya Kashiwagi and Yukinao Sakai
    Citation: Renal Replacement Therapy 2021 7:3
  27. Creating permanent vascular access (VA) is recommended before hemodialysis initiation in patients with end-stage renal disease (ESRD). Although many patients are still introduced to hemodialysis with temporary...

    Authors: Izaya Nakaya, Taijiro Goto, Yuki Nakamura, Kazuhiro Yoshikawa, Junji Oyama, Yoshihiko Tamayama, Mizuho Morooka, Sadatoshi Ito, Hirotaka Ishioka, Yuki Matsuura and Jun Soma
    Citation: Renal Replacement Therapy 2021 7:2
  28. Clinical studies of anti-glomerular basement membrane (GBM) disease were limited because of the low incidence. We aimed to report the characteristics, treatments, and outcomes of patients with anti-GBM disease...

    Authors: Yoshinosuke Shimamura, Takuto Maeda, Koki Abe, Yayoi Ogawa and Hideki Takizawa
    Citation: Renal Replacement Therapy 2021 7:1
  29. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Ryoichi Maenosono, Masayoshi Okumi, Kohei Unagami, Hironori Fukuda, Kazuhiko Yoshida, Yoichi Kakuta, Toshio Takagi, Junpei Iizuka, Tomokazu Shimizu, Haruhito Azuma, Yoji Nagashima, Kazunari Tanabe, Kosaku Nitta and Hideki Ishida
    Citation: Renal Replacement Therapy 2020 6:67

    The original article was published in Renal Replacement Therapy 2020 6:52

  30. With the increasing prevalence and incidence of chronic renal failure leading to advanced kidney disease (ESRD), the use of renal transplant therapy is increasing globally. The aim of this study was to determi...

    Authors: Arghavan Malekshahi, Hamidreza Fallah MortezaNejad, Morteza Rahbar Taromsari, Reza Ghanei Gheshlagh and Kourosh Delpasand
    Citation: Renal Replacement Therapy 2020 6:66
  31. Since 2015, the Committee of International Communication on Academic Research of the Japanese Society for Dialysis Therapy has held its Asian symposium during the society’s Annual Congress to discuss the prese...

    Authors: Toru Hyodo, Masafumi Fukagawa, Nobuhito Hirawa, Yoshitaka Isaka, Hidetomo Nakamoto, Pham Van Bui, Khin Thida Thwin and Chanseila Hy
    Citation: Renal Replacement Therapy 2020 6:65
  32. Etelcalcetide is the first intravenously administered calcimimetic agent used to manage secondary hyperparathyroidism (SHPT) in hemodialysis (HD) patients. We evaluated the safety and efficacy of replacing cin...

    Authors: Yuka Kurokawa, Yusuke Kaida, Takuma Hazama, Yosuke Nakayama, Takaomi Otome, Ryo Shibata, Sakuya Ito, Goh Kodama, Nao Nakamura, Takatoshi Kambe, Tomofumi Moriyama, Akiko Nagata, Aki Minami, Ryotaro Ando, Yoshifumi Wada, Miki Sugiyama…
    Citation: Renal Replacement Therapy 2020 6:64
  33. Gastroparesis is frequently overlooked and difficult to treat. The diagnosis of gastroparesis requires standard upper gastrointestinal endoscopy to exclude gastric outlet obstruction and objective evidence dem...

    Authors: Eriko Eguchi
    Citation: Renal Replacement Therapy 2020 6:62
  34. There is a higher frequency of advanced chronic kidney disease (CKD) in frail patients than in the general population. This study evaluated frailty status before initiation of dialysis and clarified the progno...

    Authors: Masaki Yoshida, Yurie Takanashi, Takako Harigai, Noriyuki Sakurai, Keiko Kobatake, Hiroaki Yoshida, Satsuki Kobayashi, Takayuki Matsumoto and Kazue Ueki
    Citation: Renal Replacement Therapy 2020 6:60
  35. Complications of acute kidney injury (AKI) are common in patients with coronavirus disease in 2019 (COVID-19). However, clinical characteristics of COVID-19-associated AKI are poorly described. We present two ...

    Authors: Takuya Fujimaru, Keiki Shimada, Takayuki Hamada, Kimio Watanabe, Yugo Ito, Masahiko Nagahama, Fumika Taki, Shutaro Isokawa, Toru Hifumi, Norio Otani and Masaaki Nakayama
    Citation: Renal Replacement Therapy 2020 6:59
  36. The expected remaining lifetime of dialysis patients in Japan was only reported in 2003 and has not been reported thereafter. From 2003 to the present, several new therapeutic agents have been introduced. Thes...

    Authors: Shigeru Nakai, Atsushi Wada, Kenji Wakai, Masanori Abe and Kosaku Nitta
    Citation: Renal Replacement Therapy 2020 6:58
  37. Peritoneal dialysis (PD) is associated with various complications, some of which may result in its discontinuation. Pleuroperitoneal communication (PPC) is commonly recognized by the presence of a diaphragmati...

    Authors: Jun Ino, Haruna Kaneko, Eri Kasama, Mio Kodama, Keitaro Sato, Hitoshi Eizumi and Kosaku Nitta
    Citation: Renal Replacement Therapy 2020 6:57
  38. Catheter dysfunction, especially omental wrapping, is a serious complication of peritoneal dialysis (PD). Although catheter implantation at a lower site was reported to prevent omental wrapping, this method co...

    Authors: Kyohei Ogawa, Yukio Maruyama, Nanae Matsuo, Yudo Tanno, Ichiro Ohkido, Keita Hirano, Masato Ikeda and Takashi Yokoo
    Citation: Renal Replacement Therapy 2020 6:56
  39. Renal transplant recipients with chronic kidney disease (CKD) often develop abnormal glucose metabolism. Although recent studies have reported the protective effects of sodium-glucose transport protein 2 (SGLT...

    Authors: Ryoichi Miyazaki, Kyoko Miyagi and Misaki Yoshida
    Citation: Renal Replacement Therapy 2020 6:55
  40. Hemodialysis patients have a greater risk of cardiovascular disease, their major cause of death. Obesity is a risk factor for arteriosclerosis, cardiovascular disease, and mortality in the general population. ...

    Authors: Takeshi Iida, Satoshi Morimoto, Hidenobu Okuda, Yoshifumi Amari, Takatomi Yurugi, Fumitaka Nakajima and Atsuhiro Ichihara
    Citation: Renal Replacement Therapy 2020 6:54
  41. Cholesterol embolization syndrome (CES) is a disease associating with the systemic cholesterol crystal embolism and end-organ dysfunction due to the atherosclerotic plaque rupture, which is dominantly triggere...

    Authors: Kota Kakeshita, Tsutomu Koike, Teruhiko Imamura, Yu Arisawa, Sayaka Murai, Ayako Shimizu, Taigo Kiyosawa, Hidenori Yamazaki and Koichiro Kinugawa
    Citation: Renal Replacement Therapy 2020 6:53
  42. BK polyomavirus (BKPyV) infection after kidney transplantation is an important cause of graft failure among kidney transplant recipient and may cause malignant tumor, although the association between BKPyV inf...

    Authors: Ryoichi Maenosono, Masayoshi Okumi, Kohei Unagami, Hironori Fukuda, Kazuhiko Yoshida, Yoichi Kakuta, Toshio Takagi, Junpei Iizuka, Tomokazu Shimizu, Haruhito Azuma, Yoji Nagashima, Kazunari Tanabe, Kosaku Nitta and Hideki Ishida
    Citation: Renal Replacement Therapy 2020 6:52

    The Correction to this article has been published in Renal Replacement Therapy 2020 6:67

  43. The annual survey questionnaires of the Japanese Society for Dialysis Therapy Renal Data Registry (JRDR) were sent to 4458 dialysis facilities at the end of 2018; 4402 facilities (98.7%) responded to the facil...

    Authors: Kosaku Nitta, Masanori Abe, Ikuto Masakane, Norio Hanafusa, Masatomo Taniguchi, Takeshi Hasegawa, Shigeru Nakai, Atsushi Wada, Takayuki Hamano, Junichi Hoshino, Nobuhiko Joki, Shunsuke Goto, Minako Wakasugi, Keiichi Yamamoto and Hidetomo Nakamoto
    Citation: Renal Replacement Therapy 2020 6:51
  44. Metabolic acidosis is common in hemodialysis (HD) patients. The KDOQI guidelines therapeutic goal is pre-dialysis HCO3− ≥ 22 mmol/L. The aim of the study was to evaluate an individualized HCO3− hemodialysis presc...

    Authors: Rita Valério Alves, Hernâni Gonçalves, Karina Lopes, Flora Sofia and Ana Vila Lobos
    Citation: Renal Replacement Therapy 2020 6:50

Annual Journal Metrics

  • 2022 Citation Impact
    1.2 - 2-year Impact Factor
    0.703 - SNIP (Source Normalized Impact per Paper)
    0.438 - SJR (SCImago Journal Rank)

    2023 Speed
    12 days submission to first editorial decision for all manuscripts (Median)
    137 days submission to accept (Median)

    2023 Usage 
    545,038 downloads
    139 Altmetric mentions